Sangui BioTech International Inc.
- WKN: 906757
- ISIN: US80105B1017
- Land: Germany
Nachricht vom 02.06.2015 | 15:00
Sangui BioTech International Inc.: Practitioners present wound healing case studies under Granulox treatment
Sangui BioTech International Inc. / Key word(s): Study results
SanguiBioTech: Practitioners present wound healing case studies under Granulox treatment
European Wound Management Congress shows increasing interest in Granulox as a successful approach to support wound therapies
Witten, Germany, June 2, 2015 - This year's annual congress of the European Wound Management Association (EWMA, May 13 - 15, 2015) in London staged medical researchers and practitioners from different European countries who reported about successful treatment of chronic wounds using the Sangui developed Granulox medical device, distributed by global licensee SastoMed GmbH. Presented were results of studies and series of therapies carried out in Birmingham and Brentwood (United Kingdom), Ljubljana (Slovenia), Zurich (Switzerland) as well as Frankfurt (Germany).
Well attended was a symposium chaired by professor Joachim Dissemond of Essen University, on invitation of SastoMed GmbH. Speakers included Assistant Professor Severin Läuchli, Head of the Department of Dermatology of the University Hospital in Zurich/Switzerland, who presented numerous case studies and came to the conclusion that the additional use of Granulox is able to induce granulation in a large share of previously non healing wounds and that this therapeutic option means a significant improvement for patients.
Dr. Paul Chadwick and Joy Tickle are members of an expert panel convened in the United Kingdom and assessing healing technologies designed to improve wound care standards. They presented the first national consensus recommendation on use of topical hemoglobin spray for the treatment of chronic wounds. The recommendation is based on a diligent assessment of all available scientific data as well an own set of individual trials to assess viability and effectiveness of a Granulox treatment. (cf. www.wounds-uk.com, EWMA 2015 Special Edition).
In one of the plenary sessions, moreover, Assistant Professor Joachim Klode presented initial results of a study regarding the use of photo-acoustic tomography, an innovative imaging process which was deployed to reliably image and quantify the concentration of oxygenated and des-oxygenated hemoglobin in wounds. This enables practitioners to verify and document the systematic connection between improved oxygenation as induced by the use of Granulox on the one hand and the observed improvements of healing and patient quality of life on the other. Another presentation held in this session was based on a 72 patient study. The statistical assessment and simulated extrapolation of healing processes indicated a significant improvement of wound healing under a treatment with Granulox.
The proceedings of the Congress demonstrate an increasing international regard to the innovative hemoglobin spray aimed to support the healing of chronic wounds. It also exemplifies what an intensive and persistent discussion within the expert community it takes to promote the market entry of a completely innovative treatment.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
2015-06-02 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Sangui BioTech International Inc.: Practitione ...
Sangui BioTech International Inc.: Lower reven ...
Sangui BioTech International secures financial ...
Sangui BioTech International Inc.: Series of p ...
Sangui BioTech International Inc.: Revenues sl ...
EQS Group: Rating lautet Kaufen
Die Vorzeichen für die EQS Group AG sind positiv. Ein wesentlicher Umsatztreiber für das Jahr 2020 sollte die Migration von Bestandskunden vom COCKPIT in das COCKPIT 2.0 bedeuten. Darüber hinaus erwarten wir ein gutes Wachstum in den übrigen Bereichen, da die EQS mit vielen Produkten auch von der Coronakrise profitieren kann. So werden z. B. Online-Hauptversammlungen, Webcasts und Telefonkonferenzen vermehrt gebucht: Unseres Erachtens sollte es auch zu einer höhere Anzahl an Pflichtmeldungen von Unternehmen kommen. Unser Kursziel liegt bei 91,50 €, das Rating lautet weiter Kaufen.
Der AKTIONÄR News
24. Mai 17:46 Lufthansa: Das sind die ersten Ziele!
24. Mai 09:33 McDonald's hilft – aber der Weg wird noch sehr hart
23. Mai 17:20 Alibaba: Darum fällt die Aktie nach den Zahlen wirklich
News im Fokus
Linde Recognized as a Leader in Diversity & Inclusion by DiversityInc
22. Mai 2020, 11:59
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
20. Mai 2020